Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Abstract

PURPOSE Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab in this population (ClinicalTrials.gov identifier: NCT03776136 ). METHODS Eligible patients with unresectable stage III-IV melanoma with confirmed progressive disease (PD) within 12 weeks of the last dose of a PD-1/L1 inhibitor given alone or with other therapies, including cytotoxic T-cell lymphocyte–associated antigen 4 (CTLA-4) inhibitors, received lenvatinib 20 mg orally once daily plus ≤ 35 doses of pembrolizumab 200 mg intravenously once every 3 weeks until PD or unacceptable toxicity. The primary end point was objective response rate (ORR) per RECIST, version 1.1, by independent central review. RESULTS A total of 103 patients were enrolled and treated. The median study follow-up was 15.3 months. ORR in the total population was 21.4% (95% CI, 13.9 to 30.5), with three (2.9%) complete responses and 19 (18.4%) partial responses. The median duration of response was 8.3 months (range, 3.2-15.9+). ORR was 33.3% in the 30 patients with PD on prior anti–PD-1 plus anti–CTLA-4 therapy. The median progression-free survival and overall survival in the total population were 4.2 months (95% CI, 3.8 to 7.1) and 14.0 months (95% CI, 10.8 to not reached), respectively. Grade 3-5 treatment-related adverse events occurred in 47 (45.6%) patients, most commonly hypertension (21.4%); one patient died from a treatment-related event (decreased platelet count). CONCLUSION Lenvatinib plus pembrolizumab provides clinically meaningful, durable responses in patients with advanced melanoma with confirmed PD on prior PD-1/L1 inhibitor-based therapy, including those with PD on anti–PD-1 plus anti–CTLA-4 therapy. The safety profile was as expected. These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need.

Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature

“…The combination of bevacizumab and ipilimumab was safely administered in patients with metastatic melanoma ( 27 ). Finally, strategies combining anti-angiogenic and anti-PD1 agents have been studied and appears to tip the balance of the tumor microenvironment and improve treatment response in advanced melanoma ( 28 , 29 ). These results support the efficacy of anti-angiogenic agents with ICI and further investigation.…”

Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?

“…This abundance of trials utilizing approved checkpoint inhibitor immunotherapies suggests that near-term progress in the treatment of melanoma will likely come through the use of these therapies in different treatment contexts or in combination with adjunct therapies. Supporting this trend is the recent initiation of trials in the neoadjuvant setting, and early results showing benefit for combination therapies such as pembrolizumab and lenvatinib for refractory melanoma cases [ 45 ]. Additional trials studied the ideal sequencing of immune and targeted therapies for advanced BRAF mutated melanoma and have shown superiority in survival and response rates when ICI are used as first-line over BRAF/MEK targeted therapies [ 46 ].…”

Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

“…Ample pre-clinical research is currently focusing on answering this question and we endeavor to address some of it later in this review. From a clinical standpoint, promising results were recently reported by the LEAP-004 study [ 72 ]. In this single-arm phase 2 study, patients who were exposed and whose disease had progressed on anti-PD-1/PD-L1-based immunotherapy, were treated with the combination of pembrolizumab plus lenvatinib.…”